Nonalcoholic fatty liver disease: An independent risk factor for colorectal neoplasia

Journal of Internal Medicine

Volumn 270, Issue 1, 2011, Pages 41-49

  Stadlmayr, A ^a   Aigner, E ^a,b   Steger, B ^a   Scharinger, L ^a   Lederer, D ^a   Mayr, A ^a   Strasser, M ^a   Brunner, E ^c   Heuberger, A ^c   Hohla, F ^a   Steinwendner, J ^d   Patsch, W ^b   Datz, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c Oberndorf Hospital   (Austria)

^d NONE   (Austria)

Author keywords

Colorectal carcinoma; Insulin resistance; NAFLD; Screening colonoscopy; Ultrasound examination

Indexed keywords

ANTIDIABETIC AGENT; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADENOMATOUS POLYP; ADULT; ADVANCED CANCER; ARTICLE; BODY MASS; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CHOLESTEROL BLOOD LEVEL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; ECHOGRAPHY; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PATIENT REFERRAL; PRIORITY JOURNAL; RISK FACTOR; SERODIAGNOSIS; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; CARCINOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC METHODS; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 79959344354     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02377.x     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7.
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
4. Thiis-Evensen E, Hoff GS, Sauar J, Vatn MH. Patient tolerance of colonoscopy without sedation during screening examination for colorectal polyps. Gastrointest Endosc 2000; 52: 606-10.
5. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-81.
6. Schmiegel W, Reinacher-Schick A, Arnold D et al. [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol 2008; 46: 799-840.
7. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010; 60: 99-119.
8. Ogunleye AA, Ogston SA, Morris AD, Evans JM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009; 101: 1199-201.
9. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998; 147: 816-25.
10. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 587-94.
11. Kaaks R, Toniolo P, Akhmedkhanov A et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-600.
12. Schoen RE, Weissfeld JL, Kuller LH et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology 2005; 129: 464-75.
13. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-50.
14. Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-42.
15. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-9.
16. Melchionda N, Forlani G, Marchesini G, Baraldi L, Natale S. WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance. Int J Obes Relat Metab Disord 2002; 26: 90-6.
17. Mikhail N. The metabolic syndrome: insulin resistance. Curr Hypertens Rep 2009; 11: 156-8.
18. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
19. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13-5.
20. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
21. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
22. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95: 3053-63.
23. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002; 12: 1-9.
24. Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991; 86: 946-51.
25. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
26. Kim JH, Lim YJ, Kim YH et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev 2007; 16: 1543-6.
27. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol 2005; 20: 1410-5.
28. Hwang ST, Cho YK, Park JH et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010; 25: 562-7.
29. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009; 15: 5141-8.
30. Pelucchi C, Negri E, Talamini R et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010; 46: 1866-72.
31. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-84.
32. van Kruijsdijk RC, van der WE, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009; 18: 2569-78.
33. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009; 10: 412-9.
34. Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 2011; 104: 51-9.